COOPERATIVE STUDY OF CANCER CHEMOTHERAPY

癌症患者将接受第三阶段方案的治疗 西南肿瘤学小组利用跨学科方法 手术、放射治疗、化疗(包括可变时间表 和药物的组合，包括研究药物和 已经证实并被接受的药物，无论是单独或与 放射治疗；这些形式的治疗将代表目前最 通过小组研究确定的有效药物组合)，以及免疫- 心理治疗。对上述治疗无效的患者将被 使用经过仔细评估的新的实验试剂进行管理 剂量和毒性，并显示出抗肿瘤的提示证据 对特定恶性肿瘤的影响。这些将代表第二阶段 西南肿瘤学小组的方案研究。 利用上述患者资料进行的辅助研究正在进行评估。 方案将与其他组织的研究活动协调 病理学、免疫学、生物化学、 药理学和解剖学，通过独立的赠款支持。具体来说- Cally，新墨西哥大学流动实验室将作为 西南地区开展流式细胞术的转诊机构 肿瘤学小组。UNM还将继续进行细胞表面标记 不同西南肿瘤组白血病方案分析。 新墨西哥大学一直是科学研究的主要贡献者 过去的西南肿瘤学小组，这将继续是 机构的首要任务。此外，招募医疗人员 服务不足的人群(特别是西班牙裔和美国印第安人)和 女性到西南肿瘤学小组的研究将继续是一个主要的 新墨西哥大学的承诺。

Patients who have cancer will be treated with Phase III protocols of the Southwest Oncology Group in an interdisciplinary approach utilizing surgery, radiotherapy, chemotherapy (which includes variable schedules and combinations of drugs, including both investigational agents and already proven and accepted drugs, either alone or in combination with radiotherapy; these forms of therapy would represent the current most effective drug combinations identified by group studies), and immuno- therapy. Patients who are unresponsive to the above therapy will be managed with new experimental agents, which have been carefully evaluated for dosage and toxicity, and which show suggestive evidence of anti-tumor effect in specific malignancies. These will represent the Phase II protocol studies of the Southwest Oncology Group. Ancillary studies utilizing patient material being evaluated in the above protocols will be coordinated with research activities of other departments in the areas of pathology, immunology, biochemistry, pharmacology, and anatomy through independent grant support. Specifi- cally, the University of New Mexico flow lab will function as one of the referral institutions performing flow cytometry for the Southwest Oncology Group. UNM will also continue to perform cell surface marker analyses on various Southwest Oncology Group leukemia protocols. The University of New Mexico has been a major scientific contributor to the Southwest Oncology Group in the past and this will remain one of the institution's top priorities. In addition, the recruitment of medically underserved populations (specifically Hispanic and American Indian) and women to Southwest Oncology Group studies will continue to be a major commitment of the University of New Mexico.